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Vaccines based on recombinant attenuated bacteria represent a potentially safe 
and effective immunization strategy. A carrier system was developed to analyze in 
vitro whether foreign T cell epitopes, inserted in the outer membrane protein 
PhoE of Escherichia coli and expressed by recombinant bacteria, are efficiently 
processed and presented via human leukocyte antigen (HLA) class I and I1 
molecules by bacterial infected human macrophages. A well-defined HLA- 
B27-restricted cytotoxic T cell (CTL) epitope and an HLA-DR53 restricted T 
helper (Th) epitope of the fusion protein of measles virus were genetically 
inserted in a surface-exposed region of PhoE, and the chimeric proteins were 
expressed in E. coli and Salmonella typhimurium. Macrophages infected with 
both recombinant bacteria presented the Th epitope to the specific CD4+ T cell 
clone, but failed to present the CTL epitope to the specific CD8+ Tcell clone. 
Presentation of the Th epitope by the infected macrophages was inhibited by 
cytochalasin D, indicating that phagocytic processing of intact bacteria within 
infected macrophages was essential for antigen presentation via HLA class 11. 
Presentation of theTh epitope to the CD4+ T cell clone by infected macrophages 
was blocked by brefeldin A and cycloheximide, indicating the requirement of 
nascent HLA class I1 molecules for presentation. The efficiency of macrophages 
to process and present the inserted T h  epitope was similar for both the 
recombinant E. coli and S. typhimurium strains. 
1 Introduction 
Avirulent Salmonella strains have been generated to be 
used as live Salmonella vaccine [l]. These attenuated 
Salmonella strains and several E. coli strains have also been 
evaluated for their ability to present heterologous antigens 
to the immune system [2-81. In such recombinant strains 
bacterial carrier proteins are frequently employed to 
present inserted antigenic determinants in the appropriate 
immunogenic form to the immune system of the host. 
While the T cell-mediated immune response to intracellu- 
larly residing bacteria was initially thought to be solely 
mediated by CD4+ Tcells, the additional role of CD8+ 
Tcells is now generally accepted [9]. The role of CD8+ 
T cell-mediated immunity against intracellular bacteria has 
first been shown for Listeria monocytogenes [lo, 111. Since 
L. monocytogenes enters the cytosol after lysis of the 
phagosome, the peptides presented by MHC class I mole- 
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cules were originally thought to be generated from degrad- 
ation of bacterial proteins in the cytosol [12]. However, it 
has recently been shown that listerial antigens can also be 
introduced into the MHC class I pathway independent of 
the egression of L. monocytogenes from the phagosome 
[13]. The ability of Mycobacterium [14, 151 and Salmonella 
[16,17], which reside intracellularly within phagosomes, to 
elicit specific CD8+ T cell responses in vivo, underlines the 
possibility that antigens located within the endosomal 
compartment can be presented by MHC class I molecules. 
Moreover, oral immunization of mice with attenuated 
S. typhimurium strains expressing heterologous antigens 
was shown to induce a specific CD8+ T cell response [ 181, 
which in some cases conferred protective immunity to the 
specific pathogen [8]. The processing pathway for presen- 
tation of T cell epitopes expressed by the phagosomally 
residing E. coli and S. typhimurium has recently been 
studied in vitro using peritoneal mouse macrophages [19, 
201. It was observed that theT cell epitopes were efficiently 
processed and presented via MHC class I and 11. In 
contrast, other groups have not been able to show class I 
presentation in vitro of recombinant bacterial antigens by 
cells infected with S. typhimurium [7, 211. 
We have previously shown that both B- and T-cell epitopes 
can be inserted within the surface-exposed regions of the 
E. coli outer membrane protein PhoE without disturbing 
the biogenesis of the protein (for a review see [22]). Each 
monomer of this trimeric protein traverses the outer 
membrane 16 times in an antiparallel P-sheet structure, 
thereby exposing eight regions at the cell surface [23]. In 
the rat system, using purified chimeric PhoE trimers, CD4+ 
T cell responses specific to an inserted epitope have been 
observed in vitro and in vivo [24, 251. 
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In the present study, an in vitro model system was 
developed to analyze the applicability of the PhoE carrier 
protein to permit presentation of inserted T cell epitopes 
via HLA class 1 and I1 by human macrophages infected 
with recombinant bacteria. Well-defined CTL and Th 
epitopes of measles virus were employed and the efficacy of 
recombinant E. coli and an attenuated S. typhimurium 
strain to present the epitopes were compared. 
2 Materials and methods 
2.1 Bacterial strains and growth conditions 
The E. coli K-12 strain CE1224 produces no pore proteins 
due to mutations in the phoE and ompR genes [26]. The S. 
typhimurium strain SL3261, obtained from B. A. D. 
Stocker (Stanford University, CA), is unable to synthesize 
aromatic amino acids and is therefore avirulent, but it has 
not lost its ability to enter (non-) phagocytic cells [1]. 
Bacteria were grown overnight at 37 "C under aeration in 
Luria-Bertani (LB) medium, supplemented where necessa- 
ry with ampicillin (50 pg/ml). Bacteria were inactivated by 
heat treatment for 15 min at 100°C. 
2.2 MVF peptides and T cell clones 
Synthetic peptides corresponding to the T cell epitopes of 
MVF, peptide 437-447 (CTL epitope) and peptide 453-464 
(Th epitope), were prepared by solid-phase synthesis [27]. 
The isolation, maintenance and properties of the MVF- 
specific CD4+ (JP-F94) and CD8+ (WH-F40) T cell clones 
used have been described [27]. The T cell clones JP-F94 and 
WH-F40 recognize the epitopes PPISLERLDVGT (amino 
acid residues 453-464) and SRRYPDAVYLH (residues 
437-447) in association with HLA-DR53 and HLA-B27, 
respectively [27]. 
2.3 Construction and characterization of the chimeric 
PhoE proteins 
Chimeric proteins consisting of the E. coli PhoE protein 
with insertions of the Th or CTL epitope of MVF were 
genetically constructed by the strategy described previously 
[24]. Restriction enzymes and other DNA modifying 
enzymes were purchased from Pharmacia (Uppsala, Swed- 
en). The expression vector pMR08 contains the phoE gene 
with a Bam HI linker insertion [28]. PMR08 was digested 
with Bam HI and ligated withT4 DNA ligase to the linkers 
encoding the Tcell epitopes (Fig. 1). Insertion in the wrong 
orientation would result in the introduction of a stop codon 
in the reading frame of PhoE. Correct insertion of the 
linkers was verified by sequencing using the T7 DNA 
polymerase sequencing kit (Pharmacia, Uppsala, Sweden). 
The plasmids containing the CTL- and Th epitope were 
designated pRM30 and pRM31, respectively. Plasmid 
pRMOl contains the wild-type phoE gene behind the lac 
promoter [29]. The recombinant phoE genes were inserted 
behind the lac promoter by digestion of pRM30, pRM31 
and pRMO1 with Mlul and BglII and ligation of the 
appropriate DNA fragments with T4 DNA ligase. The 
resulting plasmids encoding PhoE with the inserted CTL 
and Th epitopes were designated pRM40 and pRM41, 
respectively. 
2.4 Human macrophages 
Tissue culture reagents were obtained from Gibco Labora- 
tories (Grand Island, NY). Cells were cultured in complete 
medium: RPMI 1640 supplemented with 10% heat-inacti- 
vated fetal calf serum (FCS-c), penicillin (100 IU/ml) and 
streptomycin (100 pg/ml). PBMC were isolated from 
heparinized blood samples of healthy €€LA-matched blood 
donors by Ficoll-Paque density gradient centrifugation 
(Pharmacia, Uppsala, Sweden). PBMC were depleted of 
monocytes by differential adherence to plastic petridishes. 
The nonadherent cells were removed with pre-warmed 
(37 "C) complete medium and the adherent cells were 
harvested with a rubber policeman and ice-cold phosphate- 
buffered saline (PBS) [30]. The adherent cells, -95% 
monocytes, were seeded at a concentration of 2 x lo4 per 
well (100 pl) in 96-well round-bottom microtiter plates. To 
obtain macrophages, monocytes were cultured for 14 days 
at 37°C in a C02 incubator. During this period, the 
monocytes had acquired a macrophage morphology and 
function [31]. 
2.5 T cell proliferation assays 
HLA-matched macrophages were used as antigen-present- 
ing cells. Macrophages were incubated in RF'Ml 1640 
medium containing 10% heat-inactivated pooled human 
serum (HS-c) with various amounts of peptide, viable or 
heat-killed recombinant bacteria for 2 h at 37 "C in a C02 
incubator. Following incubation, the macrophages were 
extensively washed with RPMI 1640 and incubated for 1 h 
at 37 "C in a C02 incubator in medium containing 200 pg/ml 
gentamycin to kill extracellular bacteria [32]. The medium 
was replaced by medium containing 20 pg/ml gentamycin 
and the cells were irradiated (300 rad). The Tcell clones 
JP-F94 (2 x lo4 cells/well) or WH-F40 (5 x lo4 cells/well) 
were added to the macrophages and cultured for 3 days at 
37°C in a C02 incubator. The cells were labeled with 
[3H] thymidine during the last 18 h of culturing, harvested, 
and the incorporated radioactivity was counted in a flat-bed 
@-scintillation counter. 
2.6 Treatment of macrophages with drugs 
To determine the kinetics and requirements for antigen 
processing, the macrophages were fixed for 30 s with 0.05% 
glutaraldehyde [21] , either before or at different time 
points after incubation with the antigen preparations. The 
reaction was stopped by adding L-glycine at a final concen- 
tration of 200mM, and the macrophages were washed 
several times with RPMI 1640 containing 20 mM L-glycine. 
Subsequently, RPMI 1640 supplemented with 10% HS-c 
and 20 pg/ml gentamycin was added and the fixed macro- 
phages were used as stimulator cells in proliferation assays. 
If appropriate, the macrophages were pretreated for 30 min 
with brefeldin A (1 pg/ml), cycloheximide (10 pg/ml) or 
cytochalasin D (5 pg/ml) (Sigma, St. Louis, MO). In the 
presence of the same concentrations of inhibitors, macro- 
phages were incubated with the antigen preparations for 
2 h, washed, and reincubated for 3 h as described in Sect. 
2.5. The macrophages were then washed extensively and 
fixed with glutaraldehyde. 
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3 Results 
3.1 Construction of plasmids and characterization of 
chimeric PhoE proteins 
To study the applicability of the PhoE protein to permit the 
presentation of inserted epitopes via MHC class I and I1 in 
human macrophages, two chimeric PhoE proteins were 
constructed. Synthetic oligonucleotide linkers coding for 
the HLA-B27-restricted epitope 437-447 and for the 
HLA-DR53 restricted epitope 453-464 of MVF were in the 
DNA encoding the fourth cell-surface exposed region of 
the PhoE protein (Fig. 1). The recombinant plasmids 
encoding the chimeric PhoE proteins with either the CTL 
or the Th epitope under control of the lac promoter, were 
designated pRM40 and pRM41, and the chimeric PhoE 
proteins are referred to as PhoE-CTL4 and PhoE-TH4, 
respectively. These plasmids were used to transform the 
E. coli K-12 strain CE1224 and the attenuated S. typhimu- 
rium strain SL3261. Analysis of cell envelopes and pepti- 
doglycan-protein complexes by SDS-PAGE and Western 
immunoblotting revealed that the chimeric PhoE proteins 
were constitutively expressed at high levels and assembled 
into trimers (data not shown). This indicates that the 
chimeric proteins were correctly assembled in the outer 
membrane. 
P P I S L E R L D V G T  
A GAT CCT CCA CCA ATT AGT CTC GAG CGT CTG GAT GTT GGT ACC 
GA GGT GGA T G  TCA GAG CTC GCA GAC CTA CAA CCA TGG CTA G 
STOP KpnI 
S R R Y P D A V Y L H  
B GAT CCT TCT CGT CGA TAT CCA GAT GCT GTT TAC CTG CAT 
GA AGA GCA G a  ATA GGT CTA CGA CAR U G  GAC GTA CTA G 
EEDRV STOP 
Figure 1. Nucleotide sequences of the linkers, consisting the 
complementary oligonucleotides, that were used for the insertion 
of the MVF Tcell epitopes in the fourth cell surface-exposed 
region of PhoE. The amino acid sequences of the CTL (A) and Th 
epitopes (B) are indicated above the linker. The indicated restric- 
tion enzyme sites and stop codons were included in the oligonu- 
cleotides to facilitate screening of recombinant plasmids. 
3.2 T cell recognition of human macrophages infected 
with recombinant bacteria 
To determine whether the inserted MVF Th epitope can 
correctly be presented via HLA class 11, human macro- 
phages were infected with the recombinant strains express- 
ing PhoE-TH4. The infected macrophages were able to 
process and present the inserted Th epitope to the specific 
CD4+ Tcell clone JP-F94 (Fig. 2). For both bacterial 
strains, the optimal Tcell response was observed at a 
multiplicity of infection (MOI) of 10. As expected, the 
T cell clone also responded to macrophages pulsed with the 
corresponding synthetic MVF peptide, but not to macro- 
phages infected with the recombinant bacterial strains 
expressing PhoE-CTL4 (Fig. 2). This indicates that the 
observed T cell response is not attributable to nonspecific 
mitogenic effects of bacterial products. 
To determine whether the inserted CTL epitope can 
correctly be presented via HLA class I, macrophages were 
infected with recombinant bacteria expressing PhoE- 
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Figure 2. Macrophages infected with recombinant E. coli CE1224 
and S. typhimurium SL3261 bacteria expressing theTh epitope are 
recognized by the specific CD4+ T cell clone JP-F94. Macrophages 
(2. lo4) were incubated with different concentrations of peptide 
453-464 (e), CE1224.pRM41 (0)  or SL3261.pRM41 (0) which 
express PhoE-TH4, or CE1224.pRM40 (W) and SL3261 .pRM40 
(0) which express PhoE-CTL4. The multiplicity of infection 
(MOI) is indicated. After incubation, the macrophages were 
washed extensively and proliferation of the Tcell clone was 
measured as described in Sect. 2.5. The results are expressed as 
mean [3H] thymidine incorporation f: SD of triplicate cultures. 
CTL4. In contrast to macrophages pulsed with the corres- 
ponding synthetic MVF (437-447) peptide, the infected 
macrophages were not recognized by the T cell clone 
WH-F40 (data not shown).The possibility that the bacterial 
infection disrupted the expression of HLA-B27 or accesso- 
ry molecules required for proliferation of the T cell clone, 
was excluded by the observation that the infected macro- 
phages were still able to present the synthetic MVF 
(437-447) peptide (data not shown). 
3.3 Kinetics of antigen processing in human 
macrophages 
To determine the kinetics of antigen processing, macro- 
phages were fixed with glutaraldehyde to stop processing 
before or at several time points after the addition of either 
peptide, viable or heat-killed bacteria expressing PhoE- 
TH4. Prefixation of the macrophages abolished presenta- 
tion of the Th epitope by macrophages incubated with 
either viable or heat-killed recombinant bacteria, but not 
by those incubated with the MVF peptide (453-464) 
(Fig. 3). This indicates that processing of PhoE-TH4 by 
viable macrophages is required for presentation of the Th 
epitope. Optimal presentation of the Tcell epitope was 
observed within 1-3 h und 3-5 h for macrophages incu- 
bated with heat-killed or viable bacteria, respectively. 
Maximal T cell recognition of macrophages pulsed with 
peptide was observed after 1 h of incubation (Fig. 3). No 
differences were observed between the bacterial strains 
used. 
3.4 Inhibition of presentation of the MVF T h  epitope 
by cytochalasin D, brefeldin A and cycloheximide 
To determine whether the presentation of theTh epitope by 
infected macrophages was actually due to phagocytic 
processing of intact bacteria, rather than to processing of 
408 G. M. G. M.Verjans, R. Janssen, F. G. C. M. UytdeHaag et al. Eur. J. Immunol. 1995. 25: 405-410 
8 ,  I 4 Discussion 
Figure 3. Kinetics of processing of PhoE-TH4 expressed by recom- 
binant E. coli CE1224 and S. typhimurium SL3261 bacteria by 
human macrophages for presentation of the Th epitope. Macro- 
phages were incubated with peptide 453-464 (1 PM), with 
CE1224.pRM41 or SL3261.pRM41 bacteria expressing PhoE- 
TH4, or with CE1224.pRM40 expressing PhoE-CTL4. Viable or 
heat-killed bacteria (HK) were added at an MOI of 10. Cells were 
fixed with glutaraldehyde before (t = 0 h) or at different time 
points after antigen exposure. Proliferation of the specific CD4+ 
Tcell clone JP-F94 was measured. The results are expressed as 
mean ["H] thymidine incorporation f SD of triplicate cultures. 
PhoE-TH4 released from lysed bacteria, cytochalasin D 
was used. Cytochalasin D inhibits the phagocytic capability 
of cells [33]. Treatment of macrophages with cytochalasin D 
before incubation with the viable recombinant bacteria of 
both strains expressing PhoE-TH4 abolished the prolifera- 
tive response of the Tcell clone JP-F94 (Fig. 4). On the 
other hand, cytochalasin D-treated macrophages showed 
optimal T cell stimulation upon incubation with peptide or 
heat-killed bacteria. 
Pretreatment of macrophages with brefeldin A or cyclohex- 
imide inhibited the presentation of the Th epitope after 
incubation with either viable or heat-killed recombinant 
bacteria (Fig. 4). No differences were observed between 
the bacterial strains. In contrast, drug-treated macrophages 
were still able to present the MVF (453-464) peptide. 
We have previously shown in the rat system that purified 
chimeric PhoE proteins containing class 11-restricted T cell 
epitopes are, both in vitro and in vivo, presented to CD4+ 
T cells [24,25].We have now demonstrated that aTh epitope 
expressed as chimeric PhoE protein in E. coli and atte- 
nuated S. typhimurium is efficiently processed and pre- 
sented to human CD4+ T cells by infected human macro- 
phages. 
In contrast to E. coli K-12, S. typhimurium survives within 
macrophages by inhibiting the fusion of phagosome and 
lysosome [34]. Since phagosomefiysosome fusion is 
required for processing and presentation of internalized 
bacterial antigens by class I1 molecules [35],  we com- 
pared the antigen processing kinetics of PhoE-TH4 in 
macrophages infected with either the E. coli 
strain CE1224.pRM41 or the S. typhimurium strain 
SL3261.pRM41. Surprisingly, maximal presentation of the 
inserted epitope was observed within a similar time period 
for both bacterial strains, i.e. 3-5 h after infection. There- 
fore, the survival of both strains within human macro- 
phages was analyzed. The number of viable intracellular 
E. coli (CE1224.pRM41) bacteria declined rapidly upon 
internalization. S. typhimurium (SL3261.pRM41), entered 
the macrophages approximately tenfold more efficiently 
than the E. coli strain and multiplied intracellularly within 
the first 3 h of infection, but was killed effectively upon 
further incubation (data not shown). It should be noted 
that these observations are only indicative for the survival 
of the total population of intracellular bacteria and not for 
individual bacteria. It has been observed that a significant 
amount of S. typhimurium-containing phagosomes do fuse 
with lysosomes [34].The higher numbers of S. typhimurium 
internalized, and the amount of S. typhimurium containing 
phagolysosomes formed, is possibly sufficient to generate 
the limited amount of MHC/peptide-complexes required 
for T cell activation, resulting in similar antigen processing 
kinetics as for E. coli. When heat-killed bacteria were used, 
maximal T cell activation was already observed between 
1-3 h after incubation. Probably, the PhoE-TH4 protein 
within the heat-killed bacterial preparations is directly 
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Figure 4. Inhibition of the presentation of the 
Th epitope via HLA class I1 by human macro- 
phages, infected with recombinant E. coli 
CE1224 (A) or S. typhimurium SL3261 (B) 
bacteria, by brefeldin A ,  cycloheximide or 
cytochalasin D. Macrophages were incubated 
with peptide 453-464 (1 y ~ ) ,  with 
CE1224.pRM41 or SL3261.pRM41 bacteria 
expressing PhoE-TH4, or with CE1224.pRM40 
expressing PhoE-CTL4. Viable or heat-killed 
bacteria (HK) were added at an MOI of 10. 
After incubation, the macrophages were 
washed extensively and incubated for 3 h in 
medium containing gentamycin. The drugs 
were added 30 min before incubation with the 
antigens and maintained in the culture medium 
until fixation. The cells were fixed with gluta- 
raldehyde and the proliferation of the Tcell 
clone JP-F94 was measured. The results are 
expressed as mean [3H] thymidine incorpora- 
tion k SD of triplicate cultures. 
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accessible for antigen processing after internalization, 
whereas internalized viable bacteria first have to  be 
degraded following phagosome/lysosome fusion. The time 
needed for antigen presentation by human macrophages 
incubated with either viable or heat-killed recombinant 
S. typhirnuriurn SL3261 was comparable to that reported 
for human monocytes [21]. In contrast, antigen presenta- 
tion by activated mouse peritoneal macrophages infected 
with recombinant E. coli has been shown to occur within 
30-60 min after infection 1351. The non-activated human 
monocyte-derived macrophages may be less efficient in 
processing than mature activated mouse peritoneal macro- 
phages. Alternatively, the chimeric PhoE proteins may be 
more resistant to processing than the chimeric proteins used 
in the mouse study, which are based on the cytoplasmic 
carrier protein Crl [35]. 
Macrophages fixed with glutaraldehyde before the addition 
of either viable or heat-killed bacteria expressing PhoE- 
TH4, were not recognized by the CD4+ specificT cell clone. 
This result indicates that for both viable and heat-killed 
bacteria, antigen processing occurred exclusively intracel- 
lularly after internalization. The observation that cytochal- 
asin D inhibited the presentation of the TI, epitope by 
macrophages incubated with viable recombinant bacteria 
underlines the notion that processing of intact bacteria is 
dependent on phagocytosis 120, 351. In contrast, antigen 
presentation by macrophages incubated with heat-killed 
bacteria was not abolished by cytochalasin D, indicating 
that PhoE-TH4 within these bacterial preparations is most 
likely present in small membrane fragments that can be 
internalized via a cytochalasin D-resistant pathway, e.g. 
pinocytosis. The observation that cycloheximide and bre- 
feldin A inhibit antigen presentation by macrophages 
incubated with either viable or heat-killed recombinant 
bacteria suggests the requirement for ongoing synthesis of 
HLA class I1 molecules and their subsequent transport 
from the endoplasmic reticulum to the Golgi apparatus. 
These findings are consistent with several reports showing 
that both drugs block class I1 mediated presentation of 
whole antigens but not of synthetic peptides 121, 36, 371. 
No evidence was found for recognition of human macro- 
phages, infected with recombinant bacteria expressing 
PhoE-CTU, by the specific CD8+ Tcell clone. This 
inability of bacteria-infected macrophages to confer pre- 
sentation of antigenic determinants via class I is in contrast 
to other reports 119,201. In those studies, activated murine 
peritoneal macrophages were used as antigen-presenting 
cells, and a class I-restricted T cell epitope was expressed as 
chimeric protein in E. coli or S. typhirnuriurn [19, 201. In 
addition to the soluble bacterial proteins Crl and MalE, the 
outer membrane protein LamB was used as carrier protein 
[20]. Since LamB and PhoE are structurally similar 1381, 
and the amounts of chimeric PhoE and LamB proteins 
expressed at the bacterial cell surface were both very high, 
these factors do probably not account for the discrepancy 
observed. One difference between the studies, which might 
be of importance is the antigen-presenting cell used. It has 
recently been shown that murine macrophages can process 
and present exogenous antigens, either in soluble form or 
bound to  beads, via class I molecules [39]. Since in that 
study [39], and in those described by others [19,20], in vivo 
matured macrophages were used as antigen-presenting cell, 
we hypothesize that the human macrophages used in the 
present study, which had differentiated in vitru from 
monocyte to macrophage, have not acquired the potential 
to process and/or present the CTL epitope upon infection 
with the recombinant bacteria. The inability of Chinese 
hamster ovary (CHO) cells to  present a CTL epitope upon 
infection with recombinant $. typhirnuriurn [7] underlines 
the proposed cell type specificity. Alternatively, the peptide 
corresponding to the CTL epitope might not be generated 
because of negative effects of flanking residues of the 
carrier protein [25, 401. Future experiments using in vivo 
matured human macrophages, and insertion of the CTL 
epitope including its native flanking residues into PhoE, 
will be directed to discriminate between these possibilities. 
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